Anisha Wharton serves as Head of Regulatory Affairs at as Senior Vice President of Marketing at AVEO Oncology, an LG Chem company, and brings more than 16 years of global regulatory leadership to support the development, registration and life-cycle management of biologics and pharmaceutical products. Prior to joining AVEO in 2021, Ms. Wharton served as Director, Global Regulatory Affairs – Oncology at Merck & Co., Inc. where she served as the Global Regulatory Lead for early and late-stage clinical development programs for advanced metastatic tumors, women’s cancers, melanoma, and multiple myeloma. While at Merck, Ms. Wharton led a global regulatory team responsible for the approval of a new dosing regimen of KEYTRUDA® across all approved adult indications in over 35 countries. Prior to Merck, she served in global Regulatory Affairs roles of increasing complexity and responsibility at Nektar Therapeutics, InterMune, Inc. (acquired by Roche), InSite Vision, Inc. (acquired by Sun Pharma), and Genentech, Inc. She helped lead a cross functional team in the approval of ESBRIET® and AZASITE®, as well as the development of a global regulatory intelligence database.  Ms. Wharton earned her Bachelor of Science degree from Clark Atlanta University and her Master of Business Administration degree from the University of San Francisco School of Management.

Deb Wall serves as the Director of Human Resources at as Senior Vice President of Marketing at AVEO Oncology, an LG Chem company, and brings more than a decade of experience leading the human resource functions of both private and public companies. Ms. Wall brings deep human resources and culture-building experience to AVEO in which she seeks to build a “People First” culture where the unique traits of employees are embraced and the patient-centric company values are the operating pillars of all employees. Prior to joining AVEO’s management team in 2023, Ms. Wall served as Senior Manager of Human Resources at ArQule, Inc., where she held various human resource positions of increasing responsibility. Ms. Wall also served as Director of Human Resources for Xilio Therapeutics, Inc.

Ms. Wall earned her Bachelor of Science in Education from The State University of New York (SUNY) at Oneonta. Additionally, she holds certifications as a Myers-Briggs Type Indicator^® (MBTI) practitioner and is a certified coach. 

Noelia Rycerz brings more than 17 years of global drug development experience to her role at as Senior Vice President of Marketing at AVEO Oncology, an LG Chem company. Ms. Rycerz has held roles of increasing seniority in Clinical Operations and Program Management at Amgen Inc., Pfizer Inc., and Odonate Therapeutics, Inc. She led and executed clinical phase 1 – 3 clinical trials in varying therapeutics areas including oncology, rheumatology and cardiovascular disease. During her time at Amgen Inc. as a Program Manager, she supported CMC, Regulatory and Safety Affairs to ensure delivery of marketing applications leading to approval of Corlanor®. While at Pfizer, Ms. Rycerz was accountable for oversight of pivotal clinical trials and support of regulatory inspections leading to marketing application approvals for Xeljanz®, Besponsa® and Daurismo®. Ms. Rycerz received a Bachelors of Science at Boston University. 

Kevin Peacock currently serves as as Senior Vice President of Marketing at AVEO Oncology, an LG Chem company. Prior to joining AVEO, he served as both the Vice President, New Product Planning and Business Development at Lycera where he was leading the early commercialization process for Lycera’s novel immune-oncology compounds and in 2015 completed an exclusive strategic collaboration and license with Celgene resulting in $100M in non-dilutive financing. Mr. Peacock also previously served as Vice President, Global Marketing and Business Analytics at Dendreon, where he led the launch of Provenge^® in select European countries and managed the US Business Analytics team. Mr. Peacock was Senior Director and Product Champion for Savient Pharmaceuticals while working on Krystexxa^® and previously served as Senior Director of New Product Planning at Allos Therapeutics. Prior to that, Mr. Peacock held various roles on the ERBITUX^® brand team while at ImClone Systems. Mr. Peacock’s has extensive experience in the oncology commercialization process including marketing, market research, new product planning and product development on the R&D side. Mr. Peacock earned his Bachelor of Administration in Finance and Risk Management from Temple University.  

Manoj Patel has more than 20 years of experience in the pharmaceutical industry, over 15 of which are directly in the development of oncologic treatments and joins AVEO Oncology, an LG Chem company, as Vice President of Program Management. Prior to joining AVEO’s management team, Dr. Patel led the development of several biologics programs as a Project Leader within Teva’s specialty pharma group. Prior to Teva, he held several senior level positions within Project and Program Management as well as Customer Solutions at PRA Health Sciences (now part of ICON) and IQVIA. During his tenure at these CROs, Dr. Patel oversaw the development of oncology treatments for several major pharmaceutical and biotech clients. Prior to IQVIA, he worked at GlaxoSmithKline for more than 10 years across multiple functions that included Clinical Development, Medical Affairs and Project Management. Dr. Patel was also Sr. Director of Program and Alliance Management at ImClone Systems and was involved in the process leading to the ultimate sale of the company to Eli Lilly. Dr. Patel received BS degrees in Chemistry and Pharmacy from the University of North Carolina at Chapel Hill and a Doctorate of Pharmacy from Campbell University.

Greg Oehrtman brings over 20 years of Drug Development experience to his role returning to AVEO Oncology, an LG Chem company, after 8 years. Dr. Oehrtman has held roles of increasing seniority in Drug Development and Manufacturing at Quintiles/Catalent, Amylin, Stealth Biotherapeutics, and Dicerna. He has led both drug substance and product development and manufacturing from early pre-clinical to commercial validations, supporting development of Fast Acting Advil, Advil PM, Bydureon, FOTIVDA, Elamipretide, and Nedosiran. While in these roles, he has managed product development of small molecules, peptides, and antibodies as oral and sterile injectable along with combination device development. Dr. Oehrtman received his Ph.D in Chemical Engineering from Massachusetts Institute of Technology.

Jason Noto brings over 20 years of broad commercial leadership experience to his role as Senior Vice President of Market Access at AVEO Oncology, an LG Chem company. Prior to joining AVEO, Jason served as Vice President at 1798 Consultants, a strategic market access consultancy specializing in integrated channel strategy, patient support services (HUB), payer contract development and assessment, financial impact analysis, and related Access functions. Earlier, Jason served as Senior Director of Market Access Strategy and Payer Marketing at Amag Pharmaceuticals, leading Payer marketing efforts across all business units totaling >$600M in revenue in 2019.

Prior to his tenure at Amag Pharmaceuticals, Mr. Noto held various launch, in-line, and multi-channel marketing leadership roles of increasing responsibility at Sunovion Pharmaceuticals, Alkermes, and Bristol-Myers Squibb Company. During his career, Mr. Noto has had responsibility for the US commercial launch of various specialty products in oncology, immunology, CNS, & ultra-orphan disease states. Mr. Noto received a B.S. in Business Administration from Le Moyne College and an M.B.A. in finance from the Carroll School of Management at Boston College.

Mr. Ledell serves as Chief Operating Officer of AVEO Oncology, an LG Chem company. He joins AVEO from Enzyvant Therapeutics, a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases, where he served as Chief Operating Officer and led key business operations during the recent U.S. Food and Drug Administration approval of RETHYMIC^®. Prior to Enzyvant, Mr. Ledell served as the Chief Operating Officer at Compass Therapeutics and Horizon Discovery Group. He was responsible for leading operations at both organizations through several changes in scale. Prior to Horizon, he held multiple technology, operations and development roles at Zalicus Inc. Mr. Ledell holds a BS degree in Chemical Engineering from Worcester Polytechnic Institute.

Dr. Claudia Lebedinsky serves as Senior Vice President, Head of Clinical Development of AVEO Oncology, an LG Chem company, bringing more than 20 years of experience in oncology and clinical development to the organization.  

Dr. Lebedinsky most recently served as Vice President, Head of Clinical Development at Sumitomo Pharma Oncology (Sumitomo), where she led the clinical development of novel small molecules and peptides vaccines. Prior to her time at Sumitomo, Dr. Lebedinsky held a variety of clinical development roles for early and late phase drug development at multiple companies, including PharmaMar, Sanofi Oncology, Novartis AG and Baxalta (a subsidiary of Takeda Pharmaceutical Company, a Dyax Corporation). During this time, Dr. Lebedinsky led the development of several marketed oncology drugs, including YONDELIS^®, INREBIC^®, and ASPARLAS^®. Dr. Lebedinsky conducted her residence in medical oncology at Instituto de Oncologia Roffo, Argentina. She is a board-certified medical oncologist by Argentina Ministry of Health and Spain Ministry of Health.

Peter Kim serves as Director of Financial Planning & Analyisis of AVEO Oncology, an LG Chem company. With a financial career spanning over 27 years, Mr. Kim has held various financial roles in the pharmaceutical and banking industries. Prior to joining AVEO’s management team, he served as Associate Director, Business Planning & Analysis (Commercial) Oncology, Ophthalmology & New Launches for Sandoz Group AG (a former division of Novartis AG). During Mr. Kim’s time at Sandoz, he oversaw and supported finance matters for the oncology, base injectable and ophthalmology franchises, including new product launches within the U.S. retail space. Mr. Kim has also worked for the Federal Reserve Bank of New York, LG Electronics, CVS Pharmacy, Inc. (Express Scripts), Teva Pharmaceuticals Industries Ltd., Novartis AG, Amgen Inc. and a few other biotech companies.

Mr. Kim holds a Bachelor of Arts in Economics and Political Science from The State University of New York at Binghamton and a Bachelor of Science in Accountancy and Master of Business Administration from Saint Peter’s University.